Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cell Adhesion Molecule

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43895   clinical trials with a EudraCT protocol, of which   7301   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    22 result(s) found for: Cell Adhesion Molecule. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2006-000873-32 Sponsor Protocol Number: RGHT000255 Start Date*: 2006-08-02
    Sponsor Name:Royal Group of Hospitals Trust
    Full Title: Effect of statin therapy on monocyte function in the metabolic syndrome.
    Medical condition: Metabolic syndrome, the essential feature of which is central obesity
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001368-22 Sponsor Protocol Number: DG-041-CV-008 Start Date*: 2006-06-01
    Sponsor Name:deCODE genetics ehf.
    Full Title: A randomized, double blind, placebo controlled phase II evaluation of the pharmacokinetics, pharmacodynamics and safety of DG-041 in PAD patients
    Medical condition: Peripheral arterial disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IS (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001273-81 Sponsor Protocol Number: EFC15858 Start Date*: 2019-12-17
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: Randomized, Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated metastatic Non-Squamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors
    Medical condition: Non-small cell lung cancer metastatic
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) HU (Prematurely Ended) DE (Completed) PL (Completed) PT (Completed) BE (Completed) ES (Prematurely Ended) GR (Completed) BG (Ongoing) FR (Ongoing) IT (Ongoing) RO (Ongoing) LT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004999-19 Sponsor Protocol Number: 191001 Start Date*: 2020-06-16
    Sponsor Name:Department of infectious diseases, Hvidovre Hospital
    Full Title: Changes in weight, body composition and metabolic parameters after switch to dolutegravir/lamuvidine compared to continued treatment with dolutegravir/abacavir/lamuvidine for virologically suppress...
    Medical condition: Human immunodeficiency viruses (HIV)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10067326 Antiretroviral therapy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004471-39 Sponsor Protocol Number: IMR-SCD-301 Start Date*: 2020-06-24
    Sponsor Name:IMARA, Inc.
    Full Title: A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006644-19 Sponsor Protocol Number: CRISTAL Start Date*: 2009-01-29
    Sponsor Name:AZIENDA OSPEDALIERA SAN GERARDO DI MONZA
    Full Title: Evaluation of inflammatory immune parameters predicting cardiovascular risk in HIV-1-infected antiretroviral therapy naive patients treated with atazanavir/ritonavir versus lopinavir/ritonavir base...
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020161 HIV infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000893-68 Sponsor Protocol Number: LAED001 Start Date*: 2012-11-15
    Sponsor Name:Fundació Clinic per a la Recerca Biomèdica
    Full Title: Differences in endothelial function amongst Sitagliptin and Liraglutide Users: A randomized, open-label, parallel-group and active controlled trial
    Medical condition: type 2 diabetes patients not well controlled at the maximum tolerated dose of metformin
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-001700-39 Sponsor Protocol Number: IP-REM-PK-01-EU Start Date*: 2005-09-14
    Sponsor Name:Fresenius Biotech GmbH
    Full Title: Determination of systemic exposure and characterization of pharmacokinetics of the tri-functional antibody catumaxomab (anti-EpCAM X anti-CD3) administered intraperitoneally in EpCAM positive cance...
    Medical condition: epithelial cell adhesion molecule (EpCAM) expressing tumors in patients with malignant ascites requiring therapeutic ascites puncture
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025538 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001680-20 Sponsor Protocol Number: CCR4684 Start Date*: 2018-03-26
    Sponsor Name:Royal Marsden Hospital
    Full Title: Phase II study of ROS1 targeting with crizotinib in advanced E-cadherin negative, ER positive lobular breast cancer or diffuse gastric cancer
    Medical condition: Patients with histological confirmation of E-cadherin negative, previously treated advanced lobular breast cancer or diffuse gastric cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-003859-12 Sponsor Protocol Number: 12-027 Start Date*: 2013-07-19
    Sponsor Name:RWTH Aachen University for the Medical Faculty, represented by Clinical Trial Center Aachen (CTC-A)
    Full Title: Linagliptin as a modulator of vascular inflammation in patients with type 2 diabetes mellitus
    Medical condition: patients with type 2 diabetes mellitus and vascular inflammation
    Disease: Version SOC Term Classification Code Term Level
    17.0 10018065 - General disorders and administration site conditions 10061218 Inflammation PT
    17.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004438-18 Sponsor Protocol Number: MeIn/06/NEB-DIA/001 Start Date*: 2008-04-08
    Sponsor Name:A. Menarini Farmaceutica Internazionale s.r.l.
    Full Title: Comparative effects of Nebivolol and Carvedilol on orthostatic hypotension in hypertensive patients with type 2 diabetes mellitus (DIANECA)
    Medical condition: Orthostatic hypotension in hypertensive patients with type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031127 Orthostatic hypotension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IE (Prematurely Ended) LV (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002106-13 Sponsor Protocol Number: ATH3G10-005 Start Date*: 2017-09-06
    Sponsor Name:Athera Biotechnologies AB
    Full Title: Double-blind, randomised, placebo-controlled, multicentre, Phase IIa study to investigate the effect of phosphorylcholine human monoclonal antibody (PC-mAb) 3G10 on arterial inflammation, together ...
    Medical condition: Arterial inflammation in subjects with elevated lipoprotein a (Lp[a])
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000022953 10051615 Atherosclerotic cardiovascular disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-004884-29 Sponsor Protocol Number: 12-BI-505-02 Start Date*: 2013-01-16
    Sponsor Name:BioInvent International AB
    Full Title: A single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With BI-505, a Human Anti–Intercellular Adhesion Molecule 1 Monoclonal Antibody, In Patients With Sm...
    Medical condition: Smoldering (asymptomatic) multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-004689-32 Sponsor Protocol Number: SHP675-301 Start Date*: 2021-09-24
    Sponsor Name:Shire Human Genetic Therapies, Inc.
    Full Title: A Phase 3, Open-label Study to Evaluate the Efficacy and Safety of REPLAGAL® in Treatment-naïve Subjects with Fabry Disease
    Medical condition: Fabry disease
    Disease: Version SOC Term Classification Code Term Level
    24.1 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Ongoing) FI (Prematurely Ended) GR (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003914-15 Sponsor Protocol Number: ACT16525 Start Date*: 2020-07-21
    Sponsor Name:Sanofi-Aventis Research and Development
    Full Title: Open-label, single-arm trial to evaluate antitumor activity, safety, and pharmacokinetics of SAR408701 used in combination with ramucirumab in metastatic, non-squamous, non–small-cell lung cancer (...
    Medical condition: Non-small cell lung cancer metastatic
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) BG (Ongoing) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003438-18 Sponsor Protocol Number: AG-348inSCD Start Date*: 2020-05-14
    Sponsor Name:Julius Clinical
    Full Title: Evaluation of safety and efficacy in mitapivat sulfate in adult patients with sickle cell disease
    Medical condition: Sickle cell disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001967-26 Sponsor Protocol Number: ACT16444 Start Date*: 2021-09-16
    Sponsor Name:Sanofi aventis recherche & développement
    Full Title: Open-label study of tusamitamab ravtansine (SAR408701) in combination with ramucirumab in participants previously treated for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma with...
    Medical condition: Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001150 Adenocarcinoma gastric PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020729-42 Sponsor Protocol Number: LDOS002 Start Date*: Information not available in EudraCT
    Sponsor Name:Helix BioPharma Corp
    Full Title: A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47 as a Monotherapy in Non-Squamous Non-Small Cell Lung Cancer Patients
    Medical condition: Inoperable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-003015-34 Sponsor Protocol Number: LDOS003 Start Date*: 2018-04-12
    Sponsor Name:Helix BioPharma Corp
    Full Title: A Phase II Open-Label, Randomized Study of Immunoconjugate L-DOS47 in Combination with Vinorelbine/Cisplatin Versus Vinorelbine/Cisplatin Alone in Patients with Lung Adenocarcinoma
    Medical condition: Lung adenocarcinoma chemotherapy naive or recurrent for which vinorelbine/cisplatin would be appropriate therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025031 Lung adenocarcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000065-16 Sponsor Protocol Number: DS102A-07-CV1 Start Date*: 2020-08-11
    Sponsor Name:Afimmune Ltd.
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Dose Finding Phase IIb Study to Assess the Efficacy and Safety of Orally Administered Epeleuton in Patients with Hypertriglyceridemia and Type 2 Diab...
    Medical condition: Hypertriglyceridemia and Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.1 10027433 - Metabolism and nutrition disorders 10020870 Hypertriglyceridemia LLT
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LV (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 30 17:50:53 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA